An evaluation of current shigellosis treatment.
Shigellosis or bacillary dysentery, characterised by the passage of frequent loose stools mixed with blood and mucous, is caused by Shigella spp. which can be subdivided into four serotypes, namely, S. sonnei, S. boydii, S. flexneri and S. dysenteriae. S. dysenteriae type 1 produces severe dysentery and may be associated with many complications like leukaemoid reaction and haemolytic-ureamic syndrome. It is known to produce protracted epidemics and pandemics and is usually multi-drug resistant. Antibiotics are the mainstay of therapy of all cases of shigellosis. Antibiotics such as tetracycline, ampicillin and co-trimoxazole, were previously highly effective. Newer fluoroquinolones such as norfloxacin, ciprofloxacin, ofloxacin, azithromycin and ceftriaxone are effective. Although single dose of norfloxacin 800 mg and ciprofloxacin 1 g have been shown to be effective, they are currently less effective against S. dysenteriae type 1 infection. Oral rehydration salt should be given concurrently to prevent or correct dehydration. Antimotility agents are contraindicated. Feeding during and after shigellosis is emphasised. Hand-washing practices with plenty of water and soap help to prevent the transmission of infection from person to person. A search is on for an effective vaccine against shigella.
Bhattacharya
Sujit Kumar
SK
National Institute of Cholera and Enteric Diseases, P-33, CIT Road, Scheme XM, Beliaghata, Kolkata - 700 010, India. bsandip@cal3.vsnl.net.in
Sur
Dipika
D
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D004405:Dysentery, Bacillary / Q000150:complications / Q000188:drug therapy*; D004435:Eating; D005440:Fluid Therapy; D006801:Humans
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents